First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

<h4>Background</h4>Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective than pentaval...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Cesar Miranda-Verastegui, Gianfranco Tulliano, Theresa W Gyorkos, Wessmark Calderon, Elham Rahme, Brian Ward, Maria Cruz, Alejandro Llanos-Cuentas, Greg Matlashewski
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Public Library of Science (PLoS) 2009-07-01
Reeks:	PLoS Neglected Tropical Diseases
Online toegang:	https://hdl.handle.net/20.500.12959/403
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!